These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 29764840)

  • 1. How I diagnose and treat venous thromboembolism in sickle cell disease.
    Shet AS; Wun T
    Blood; 2018 Oct; 132(17):1761-1769. PubMed ID: 29764840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of rivaroxaban in sickle cell disease and venous thromboembolism: A case report.
    Rozi W; Ali EAH; Al-Mashdali AF; Abdelrazek M; Yassin MA
    Medicine (Baltimore); 2021 Dec; 100(51):e27988. PubMed ID: 34941038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of Direct Oral Anticoagulants in Patients with Sickle Cell Disease and Venous Thromboembolism: A Prospective Cohort Study of 12 Patients.
    Christen JR; Bertolino J; Jean E; Camoin L; Ebbo M; Harlé JR; Schleinitz N; Sarlon G; Bernit E
    Hemoglobin; 2019; 43(4-5):296-299. PubMed ID: 31724442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overcoming challenges of venous thromboembolism in sickle cell disease treatment.
    Ogunsile FJ; Naik R; Lanzkron S
    Expert Rev Hematol; 2019 Mar; 12(3):173-182. PubMed ID: 30773073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sickle cell disease and venous thromboembolism: what the anticoagulation expert needs to know.
    Naik RP; Streiff MB; Lanzkron S
    J Thromb Thrombolysis; 2013 Apr; 35(3):352-8. PubMed ID: 23435703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and safety of oral anticoagulants in patients with sickle cell disease and venous thromboembolism: a retrospective cohort study.
    Roberts MZ; Gaskill GE; Kanter-Washko J; Kyle TR; Jones BC; Bohm NM
    J Thromb Thrombolysis; 2018 May; 45(4):512-515. PubMed ID: 29556958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. THromboprophylaxis In Sickle Cell Disease with central venous catheters (THIS): an internal pilot randomised controlled trial protocol.
    Abdulrehman J; Forté S; Tomlinson G; Solh Z; Bolster L; Sun HL; Bartolucci P; Kuo KHM
    BMJ Open; 2024 Jan; 14(1):e079363. PubMed ID: 38171625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing Length of Stay Between Patients Taking Rivaroxaban and Conventional Anticoagulants for Treatment of Venous Thromboembolism.
    Desai A; Desai A; Calixte R; Aparnath M; Hindenburg A; Salzman S; Mathew JP
    Lung; 2016 Aug; 194(4):605-11. PubMed ID: 27192990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient satisfaction after conversion from warfarin to direct oral anticoagulants for patients on extended duration of anticoagulation for venous thromboembolism - The SWAN Study.
    Hendriks T; McGregor S; Rakesh S; Robinson J; Ho KM; Baker R
    PLoS One; 2020; 15(6):e0234048. PubMed ID: 32497116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
    Coleman CI; Bunz TJ; Turpie AGG
    Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and safety of outpatient rivaroxaban versus warfarin for treatment of venous thromboembolism in patients with a known primary hypercoagulable state.
    Coleman CI; Turpie AGG; Bunz TJ; Baker WL; Beyer-Westendorf J
    Thromb Res; 2018 Mar; 163():132-137. PubMed ID: 29407625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rivaroxaban for the treatment of venous thromboembolism. The SWIss Venous ThromboEmbolism Registry (SWIVTER).
    Kucher N; Aujesky D; Beer JH; Mazzolai L; Baldi T; Banyai M; Hayoz D; Kaeslin T; Korte W; Escher R; Husmann M; Frauchiger B; Baumgartner I; Spirk D
    Thromb Haemost; 2016 Aug; 116(3):472-9. PubMed ID: 27346301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Venous thromboembolism in pediatric patients with sickle cell disease: A north American survey on experience and management approaches of pediatric hematologists.
    Betensky M; Kumar R; Hankins JS; Goldenberg NA;
    Thromb Res; 2022 Mar; 211():133-139. PubMed ID: 35151008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment Challenges in Venous Thromboembolism: An Appraisal of Rivaroxaban Studies.
    Khorana AA; Weitz JI
    Thromb Haemost; 2018 May; 118(S 01):S23-S33. PubMed ID: 29566417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight.
    Perales IJ; San Agustin K; DeAngelo J; Campbell AM
    Ann Pharmacother; 2020 Apr; 54(4):344-350. PubMed ID: 31672028
    [No Abstract]   [Full Text] [Related]  

  • 16. XALIA-LEA: An observational study of venous thromboembolism treatment with rivaroxaban and standard anticoagulation in the Asia-Pacific, Eastern Europe, the Middle East, Africa and Latin America.
    Kreutz R; Mantovani LG; Haas S; Monje D; Schneider J; Bugge JP; Gebel M; Tamm M; Ageno W; Turpie AGG
    Thromb Res; 2019 Apr; 176():125-132. PubMed ID: 30825694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
    Beyer-Westendorf J; Ageno W
    Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High incidence of venous thromboembolism recurrence in patients with sickle cell disease.
    Brunson A; Keegan T; Mahajan A; White R; Wun T
    Am J Hematol; 2019 Aug; 94(8):862-870. PubMed ID: 31074115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of rivaroxaban use in patients with gynecologic malignancies at an academic medical center: A pilot study.
    Signorelli JR; Gandhi AS
    J Oncol Pharm Pract; 2019 Mar; 25(2):362-368. PubMed ID: 29157146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrence of malignancy-associated venous thromboembolism among patients treated with rivaroxaban compared to enoxaparin.
    Nicklaus MD; Ludwig SL; Kettle JK
    J Oncol Pharm Pract; 2018 Apr; 24(3):185-189. PubMed ID: 29284351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.